heart failure
Conditions
Interventions
Combination therapy group vs monotherapy group:NA
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old; 2. Meets the diagnostic criteria for heart failure, with unlimited ejection fraction (including HFrEF, HFmrEF, HFpEF); 3. During the study period, one of the following prescriptions was prescribed for the first time: Combination therapy group: Simultaneously or within 30 days, non nifedipine and any SGLT2 inhibitors (such as dapagliflozin, empagliflozin, canagliflozin, etc.) were started and continued for at least 90 days. Monotherapy group: started using any SGLT2i and did not use any MRA (including non nalide, spironolactone, and eplerenone) for at least 6 months after starting medication, and continued medication for at least 90 days; 4. The medical records are complete, with at least baseline and one or more follow-up laboratory and cardiac ultrasound data.
Exclusion criteria
Exclusion criteria: 1. Previous renal replacement therapy (dialysis or kidney transplantation); 2. Baseline blood potassium>5.0 mmol/L; 3. Baseline estimated glomerular filtration rate (eGFR)<25 mL/min/1.73 m ²; 4. Key baseline variables (such as LVEF, NT proBNP, medication start time) are missing or logically contradictory and cannot be corrected; 5. During the follow-up period, there were no clinical records (outpatient, inpatient, laboratory, prescription), making it impossible to determine the primary endpoint status; 6. Simultaneously using other mineralocorticoid receptor antagonists (such as spironolactone, eplerenone) or multiple SGLT2 inhibitors violates the definition of exposure.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Incidence rate of security incidents;Clinical outcome event incidence rate;Comprehensive improvement of cardiac function;Changes in Kidney and Metabolic Indicators;Imaging and functional indicators; | — |
Primary
| Measure | Time frame |
|---|---|
| Cardiac function evaluation; | — |
Countries
China
Contacts
Public ContactRong Jiang
Shanghai General Hospital
Outcome results
None listed